KRTAP9-2

Across TCGA pan-cancer cohorts, KRTAP9-2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KRTAP9-2 data layer compared with 8 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher KRTAP9-2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRTAP9-2 expression acts as an unfavorable survival marker.

LUAD and LIHC are the cancer types where KRTAP9-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.141	0.656	<.001	34	view →
LIHC	OS	Median	All	0.226	0.773	.008	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

KRTAP9-2–LUAD (DFS)

Open the LUAD breakdown →